Dossier
wet age-related macular degeneration
Coverage of wet age-related macular degeneration in the Nexus archive.
- STAT+: Ophthalmology venture grabs investors’ attention, raises $330 million
Ollin Biosciences, a startup developing treatments for eye diseases, raised $330 million in a Series B funding round led by TCGX and ARCH Venture Partners. The company is preparing for a Phase 3 trial of a treatment targeting diabetic macular edema and wet age-related macular degeneration.